US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

5.11

+0.30006.24%

Post-market: 4.72-0.3878-7.59%19:30 EDT

Volume:680.21K

Turnover:3.33M

Market Cap:159.89M

PE:-1.24

High:5.13

Open:4.80

Low:4.69

Close:4.81

52wk High:50.40

52wk Low:4.54

Shares:31.29M

Float Shares:18.39M

Volume Ratio:1.36

T/O Rate:3.70%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.1300

EPS(LYR):-2.8503

ROE:-59.21%

ROA:-37.36%

PB:0.73

PE(LYR):-1.79

Loading ...

Overview Company News Filings

Summit Therapeutics’ Ivonescimab Shows Phase III Survival Benefit

Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines

Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Tvardi Therapeutics to Participate in Upcoming Investor Events

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Cardiol Therapeutics initiated with a Buy at B. Riley

TenNor Therapeutics Narrows Loss and Advances Anti-Infective and CNS Pipeline

Spyre Therapeutics price target lowered to $127 from $135 at Deutsche Bank

Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints

MT Newswires Live

GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial

MT Newswires Live

Spyre Therapeutics Won't Prioritize Rheumatoid Arthritis Monotherapy After Trial

Cyclerion Therapeutics Details Merger-Related Risks and Uncertainties

Spyre Therapeutics reports Phase 2 TL1A trial results

Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Denali Therapeutics is Maintained at Buy by B. Riley Securities

B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating

MT Newswires Live

BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain

Knight Therapeutics Price Target Raised to C$11.50 at Raymond James

MT Newswires Live

Beam Therapeutics Price Target Maintained with a $80.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/LENZ/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":5.11,"timestamp":1787947200000,"preClose":4.81,"halted":0,"volume":680206,"hourTrading":{"tag":"盘后","latestPrice":4.7222,"preClose":5.11,"latestTime":"19:30 EDT","volume":13215,"amount":67343.4444,"timestamp":1787959806780,"change":-0.3878,"changeRate":-0.07589,"amplitude":0.07589},"delay":0,"changeRate":0.062370062370062526,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Market Closed","change":0.3,"latestTime":"08-28 16:00:00 EDT","open":4.8,"high":5.13,"low":4.69,"amount":3329859.3660139996,"amplitude":0.091476,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.81,"preHourTrading":{"tag":"盘前","latestPrice":4.83,"preClose":4.81,"latestTime":"09:26 EDT","volume":2073,"amount":9990.9756582,"timestamp":1787923615246,"change":0.02,"changeRate":0.004158,"amplitude":0.047838},"postHourTrading":{"tag":"盘后","latestPrice":4.7222,"preClose":5.11,"latestTime":"19:30 EDT","volume":13215,"amount":67343.4444,"timestamp":1787959806780,"change":-0.3878,"changeRate":-0.07589,"amplitude":0.07589},"volumeRatio":1.3600203139591769,"impliedVol":2.5415,"impliedVolPercentile":0.9243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":1.3600203139591769,"shares":31289969,"dividePrice":0,"high":5.13,"amplitude":0.091476,"preClose":4.81,"low":4.69,"week52Low":4.535,"pbRate":"0.73","psRate":"7.45","week52High":50.4,"institutionHeld":0,"latestPrice":5.11,"eps":-4.13,"divideRate":0,"volume":680206,"delay":0,"ttmEps":-4.13,"open":4.8,"prevYearClose":16,"prevWeekClose":4.68,"prevMonthClose":5.3,"prevQuarterClose":5.68,"fiveDayClose":4.68,"twentyDayClose":5.3,"sixtyDayClose":7.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-08-28","current":-1.237288,"percent":0.984694,"low":-26.69966,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"high":-1.14458,"avg":-10.644758,"sd":6.144645,"marketCap":151131849},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849}],"updateTime":1788117494623},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662717956","title":"Summit Therapeutics’ Ivonescimab Shows Phase III Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2662717956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662717956?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:48","pubTimestamp":1787752108,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Summit Therapeutics ( ($SMMT) ). On August 25, 2026, Summit Therapeutics highlighted positive topline results r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-ivonescimab-shows-phase-iii-survival-benefit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/summit-therapeutics-ivonescimab-shows-phase-iii-survival-benefit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4134","LENZ","BK4539","III","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662719100","title":"Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2662719100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662719100?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:15","pubTimestamp":1787746535,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating on August 17. Tyler Van Buren has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-oruka-therapeutics-citing-superior-pasi-100-data-upcoming-durability-readouts-and-accelerated-pipeline-timelines-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tyler-van-buren-reiterates-buy-on-oruka-therapeutics-citing-superior-pasi-100-data-upcoming-durability-readouts-and-accelerated-pipeline-timelines-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","LU1989763005.USD","BK4139","BK4588","LU0390134368.USD","BK4585","BK4007","LENZ","TYL","BK4539","LU1989773731.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662822719","title":"Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2662822719","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662822719?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:00","pubTimestamp":1787745600,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Aug.  26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351282/0/en/mineralys-therapeutics-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525689.USD","LU0211327993.USD","LU2361045086.USD","LU1035773651.USD","LU2461242641.AUD","BK4588","LU0211328371.USD","BK4007","LU0683600562.USD","LU1894683348.USD","LU1506573853.SGD","XLV","LU0640476718.USD","LU0289960550.SGD","LU0251142724.SGD","TFNS","BK4504","LENZ","IYF","LU0417517546.SGD","BK4137","KBWB","LU1791807156.HKD","LU0130102774.USD","BK4559","LU0971096721.USD","LU0320765489.SGD","LU1668664300.SGD","BK4581","LU0154236417.USD","LU0128526141.USD","LU2361044949.HKD","BK4501","BK4585","FTXO","LU0648001328.SGD","PGF","XBI","LU0070302665.USD","LU1814569148.SGD","LU0106831901.USD","LU0267386448.USD","IE0002270589.USD","LU0208291251.USD","LABU","LU0162691827.USD","HCSG","LU0048573561.USD","LU0868494708.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662271987","title":"Tvardi Therapeutics to Participate in Upcoming Investor Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2662271987","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662271987?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:00","pubTimestamp":1787745600,"startTime":"0","endTime":"0","summary":"HOUSTON, Aug.  26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351266/0/en/tvardi-therapeutics-to-participate-in-upcoming-investor-events.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","BK4539","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715769","title":"Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715769","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715769?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:30","pubTimestamp":1787743800,"startTime":"0","endTime":"0","summary":"Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/26/3351240/0/en/trevi-therapeutics-announces-upcoming-presentations-at-the-european-respiratory-society-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","EPV","LENZ","RCC","BK4585","BK4007","BK4539","FAS","BID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662791991","title":"Cardiol Therapeutics initiated with a Buy at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2662791991","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662791991?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:15","pubTimestamp":1787735715,"startTime":"0","endTime":"0","summary":"B. Riley initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $11 price target The firm believes the company’s lead candidate, C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cardiol-therapeutics-initiated-with-a-buy-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cardiol-therapeutics-initiated-with-a-buy-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRDL","BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662979192","title":"TenNor Therapeutics Narrows Loss and Advances Anti-Infective and CNS Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2662979192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662979192?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:08","pubTimestamp":1787735291,"startTime":"0","endTime":"0","summary":"TenNor Therapeutics Suzhou Ltd. Class H ( ($HK:6872) ) just unveiled an update. TenNor Therapeutics reported interim results for the six months to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tennor-therapeutics-narrows-loss-and-advances-anti-infective-and-cns-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tennor-therapeutics-narrows-loss-and-advances-anti-infective-and-cns-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4135","CNS","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662799134","title":"Spyre Therapeutics price target lowered to $127 from $135 at Deutsche Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2662799134","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662799134?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:40","pubTimestamp":1787733618,"startTime":"0","endTime":"0","summary":"Deutsche Bank lowered the firm’s price target on Spyre Therapeutics (SYRE) to $127 from $135 and keeps a Buy rating on the shares following the top...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-price-target-lowered-to-127-from-135-at-deutsche-bank-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-price-target-lowered-to-127-from-135-at-deutsche-bank-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DB","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662795041","title":"Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662795041","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662795041?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:16","pubTimestamp":1787732205,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer, Summit Therapeutics said late Tuesday.The ivonescimab-based regimen showed \"statistically significant and clinically meaningful superiority\" in the study's primary endpoint of overall survival, compared with the durvalumab-based regimen, the company said.The trial, conducted in China, also met its secondary endpoints of progression-free survival and objective response rate, according to Summit Therapeutics.The company's shares were up 4.5% in premarket activity Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","SMMT","BK4139","BK4007","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662798913","title":"GenFleet Therapeutics Lung Cancer Drug Candidate Enters Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662798913","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662798913?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:55","pubTimestamp":1787727342,"startTime":"0","endTime":"0","summary":"GenFleet Therapeutics  said GFH375 entered a phase II study for first-line treatment of patients with non-small cell lung cancer.The trial will be conducted in a number of clinical sites across China, with Guangdong Provincial People's Hospital as the leading site, according to a Wednesday Hong Kong bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02595","BK4007","BK4139","BK1161","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662675221","title":"Spyre Therapeutics Won't Prioritize Rheumatoid Arthritis Monotherapy After Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662675221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662675221?lang=en_us&edition=fundamental","pubTime":"2026-08-26 05:00","pubTimestamp":1787691600,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics will not prioritize the use of its SPY072 drug candidate as a monotherapy to treat rheumatoid arthritis, saying that results from a phase 2 trial did not meet the company's threshold.Shares of the biotechnology company fell on the news, losing 13% in after-hours trading to $93.50.A substudy of the drug to treat rheumatoid arthritis, part of a broader phase 2 study focusing on rheumatic diseases, showed that high and low doses both had statistically significant benefits over a placebo on certain endpoints, Spyre said. The low dose demonstrated a statistically significant benefit on the study's primary endpoint, the company added.But the magnitude of the results missed the company's targets, it said.\"The results provide proof-of-mechanism for TL1A in RA and support its potential in other autoimmune diseases and as a combination component, but did not meet the Company's internal bar to prioritize advancement of SPY072 in RA,\" the company said. SPY072 is designed to inhi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4539","BK4139","LENZ","LFSC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662271752","title":"Cyclerion Therapeutics Details Merger-Related Risks and Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2662271752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662271752?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:51","pubTimestamp":1787691110,"startTime":"0","endTime":"0","summary":"An announcement from Cyclerion Therapeutics ( ($CYCN) ) is now available. Cyclerion Therapeutics outlined a wide range of risks and uncertainties a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cyclerion-therapeutics-details-merger-related-risks-and-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cyclerion-therapeutics-details-merger-related-risks-and-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752678","title":"Spyre Therapeutics reports Phase 2 TL1A trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752678","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752678?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:33","pubTimestamp":1787689998,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics ( ($SYRE) ) has provided an announcement. On August 25, 2026, Spyre Therapeutics reported topline results from the rheumatoid ar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-reports-phase-2-tl1a-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spyre-therapeutics-reports-phase-2-tl1a-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754700","title":"Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754700?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:05","pubTimestamp":1787688312,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced results from the RA sub-study of its Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. Both ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-results-from-ra-sub-study-of-skyway-basket-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-results-from-ra-sub-study-of-skyway-basket-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","BK4139","SYRE","BK4007","BK4539","LENZ","RA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175441","title":"Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175441?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":"Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350866/0/en/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-the-skyway-phase-2-trial-of-spy072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","SYRE","LFSC","LENZ","RA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662075927","title":"Denali Therapeutics is Maintained at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2662075927","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662075927?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:57","pubTimestamp":1787680620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DNLI/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731252","title":"B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662731252?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:55","pubTimestamp":1787658929,"startTime":"0","endTime":"0","summary":"Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $34.88, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662734852","title":"BioXcel Therapeutics Amends Credit Agreement Amid Liquidity Strain","url":"https://stock-news.laohu8.com/highlight/detail?id=2662734852","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662734852?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:51","pubTimestamp":1787658666,"startTime":"0","endTime":"0","summary":"An announcement from Bioxcel Therapeutics ( ($BTAI) ) is now available. On August 24, 2026, BioXcel Therapeutics entered into a Fourteenth Amendmen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioxcel-therapeutics-amends-credit-agreement-amid-liquidity-strain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioxcel-therapeutics-amends-credit-agreement-amid-liquidity-strain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731851","title":"Knight Therapeutics Price Target Raised to C$11.50 at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662731851?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:34","pubTimestamp":1787657684,"startTime":"0","endTime":"0","summary":"Raymond James raised its price target on Knight Therapeutics (GUD.TO) to C$11.50 from C$9.Analyst Michael W. Freeman maintained an outperform rating on shares of the Canadian speciality pharmaceutical","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662973904","title":"Beam Therapeutics Price Target Maintained with a $80.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662973904","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662973904?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:29","pubTimestamp":1787657340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAM/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}